Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
about
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphomaTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerPositron emission tomography (PET)-adapted therapy for Hodgkin lymphoma patientsTreatment including anthracyclines versus treatment not including anthracyclines for childhood cancerHodgkin's lymphoma in adults: diagnosis, treatment and follow-up.Role of Radiotherapy in Modern Treatment of Hodgkin's LymphomaHodgkin's lymphoma therapy: past, present, and future.Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.The Management of Classical Hodgkin's Lymphoma: Past, Present, and FutureFDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.FDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value.Intensified ChlVPP/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphomaThe Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal CancerPositron emission tomography imaging approaches for external beam radiation therapies: current status and future developmentsMaximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma.Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma.Positron emission tomography: current status and future challenges.Emerging drugs for Hodgkin's lymphoma.The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma.The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.PET Response-Guided Treatment of Hodgkin's Lymphoma: A Review of the Evidence and Active Clinical TrialsReview of the cardiac long-term effects of therapy for Hodgkin lymphoma.The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma.The role of autologous transplantation in Hodgkin lymphoma.Impact of FDG-PET/CT in the management of lymphoma.State of the art in the treatment of Hodgkin lymphoma.Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity.Advances in oncologic imaging: update on 5 common cancers.Current status of PET/CT in the diagnosis and follow up of lymphomas.Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma.The GHSG Approach to Treating Hodgkin's Lymphoma.PET-directed therapy in Hodgkin lymphoma: Ready for prime time?Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis.The role of FDG-PET in Hodgkin lymphomaDevelopments in oncological positron emission tomography/computed tomography assessment.Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass.
P2860
Q24186668-5C694AF0-D1E0-426E-B85B-0CA1D5E4BEDEQ24193790-EBCCB3A2-4AC2-4945-A349-BAE875D69D38Q24202622-0B2575AA-39C7-4976-90FA-26BC9381C6A7Q24234833-68DECA98-211B-4207-A644-2D1E01E790FBQ33406827-74C3B67B-8786-4F58-940D-2E6EF5BEB9CCQ34235785-AE7FE334-83FC-4F36-BBA2-841AA03FF722Q34296914-3350E642-D1E1-41EF-B1C8-6686B4D6E6FFQ34451778-650F19F5-CD04-4B46-851F-A23BC3019BB9Q34495333-A3025B29-4189-4CEB-8517-B23EC95F7B1EQ34610653-E1B34FEC-49F0-45E7-80F3-1734BECA0BE2Q34707420-211A14B1-7E3F-4CD8-99DD-629B35C9219CQ35038852-BAFABC43-4260-4F2A-BD2C-2B375AE2D93BQ35208087-6A66173A-85B2-4785-8114-FAE544CC2F6CQ35237507-9F796820-86B2-43DE-8CB5-5EA4AB1A06F2Q35602142-4264514F-C1E4-43A3-B0EA-116BBBE1ED39Q35793080-2C255B17-0A26-4C79-B9D2-093788499C4DQ36325435-35CDD2A3-4BDF-4BDB-8535-98EB7019E997Q36524619-1E30AD23-6F23-4D6D-876E-F54ECF2EF79CQ36747993-627FDA24-06C9-418D-9190-C70115AFC94EQ37766305-6017837A-4F5B-463B-B5F2-28985E1F698EQ37772513-CA74BEDD-59F6-4B15-B4D3-3F8E407BBB0BQ37775636-79903077-0810-496C-BED3-32AA68628412Q37788240-81E69A51-571A-4ABA-AAF9-ED6887433E17Q37828408-DDD1CEC0-BFA4-4A0E-870A-41BE70A0F190Q37871620-03FDC390-FF4F-4FB6-A19C-51C5BA6B9849Q37873408-0AA6D954-65CF-4522-B741-4B008008BEE4Q37874982-F85BBD7B-BC42-4133-B4C3-001825AA685CQ37950857-26D93362-BD56-40D6-8AE9-0896D234ABC3Q38017914-C2FAB60F-8FD1-4150-9CD4-C41040A7833FQ38036587-CA40B1E6-98EA-4344-85BD-60EE5384F203Q38052458-FE6C5CB5-973C-4332-A6E6-3AE4298CD15FQ38071295-963B7803-654D-407C-9C3C-6E5875B4EC3BQ38099028-3135AAEA-4CAE-4706-903F-DABB03ECF4A7Q38506223-D7ACAB9D-28D4-49D9-A594-FF14575E178AQ38608555-96B2C66E-7982-4D24-9216-8462AD12AB08Q40616101-A1CEE4EB-2B70-480F-A0FB-0E96D85B2F19Q40635561-39198CD3-B990-423B-8577-CDE707140B9AQ41691698-5F65E806-C765-46D6-847B-5C36B68654A0Q41965876-ED8602E7-D58A-4944-94F7-454DDC6656C8Q44611640-80694D46-E109-4F75-89C7-152E884BA703
P2860
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Positron emission tomography h ...... dvanced-stage Hodgkin lymphoma
@en
type
label
Positron emission tomography h ...... dvanced-stage Hodgkin lymphoma
@en
prefLabel
Positron emission tomography h ...... dvanced-stage Hodgkin lymphoma
@en
P2093
P2860
P1433
P1476
Positron emission tomography h ...... dvanced-stage Hodgkin lymphoma
@en
P2093
Andreas Engert
Andreas Lohri
Carsten Kobe
Hans T Eich
Harald Schicha
Holger Amthauer
Jana Markova
Jeremy Franklin
Josee M Zijlstra
Markus Dietlein
P2860
P304
P356
10.1182/BLOOD-2008-06-155820
P407
P577
2008-08-29T00:00:00Z